REFERENCES
1. Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64:319-34.
2. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335-47.
3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-57.
4. Kim GA, Moon JH, Kim W. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: implication of Janus-faced modernity. Clin Mol Hepatol. 2023;29:831-43.
5. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024;29:101133.
6. Dongiovanni P, Paolini E, Corsini A, Sirtori CR, Ruscica M. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. Eur J Clin Invest. 2021;51:e13519.
7. Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12:60.
8. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542.
9. Roeb E. Excess body weight and metabolic (Dysfunction)-associated fatty liver disease (MAFLD). Visc Med. 2021;37:273-80.
10. Wong VW, Ekstedt M, Wong GL, Hagström H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79:842-52.
11. Lazarus JV, Mark HE, Allen AM, et al; Healthy Livers, Healthy Lives Collaborators. A global research priority agenda to advance public health responses to fatty liver disease. J Hepatol. 2023;79:618-34.
12. Yu EL, Schwimmer JB. Epidemiology of pediatric nonalcoholic fatty liver disease. Clin Liver Dis. 2021;17:196-9.
13. Hartmann P, Zhang X, Loomba R, Schnabl B. Global and national prevalence of nonalcoholic fatty liver disease in adolescents: an analysis of the global burden of disease study 2019. Hepatology. 2023;78:1168-81.
14. Han MAT, Yu Q, Tafesh Z, Pyrsopoulos N. Diversity in NAFLD: a review of manifestations of nonalcoholic fatty liver disease in different ethnicities globally. J Clin Transl Hepatol. 2021;9:71-80.
15. Younossi ZM, Loomba R, Anstee QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68:349-60.
16. López-velázquez JA, Silva-vidal KV, Ponciano-rodríguez G, et al. The prevalence of nonalcoholic fatty liver disease in the Americas. Ann Hepatol. 2014;13:166-78.
17. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
18. Rojas YAO, Cuellar CLV, Barrón KMA, Arab JP, Miranda AL. Non-alcoholic fatty liver disease prevalence in Latin America: a systematic review and meta-analysis. Ann Hepatol. 2022;27:100706.
19. Chinchilla-López P, Ramírez-Pérez O, Cruz-Ramón V, et al. More evidence for the genetic susceptibility of mexican population to nonalcoholic fatty liver disease through PNPLA3. Ann Hepatol. 2018;17:250-5.
20. Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23:8263-76.
21. Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70:1457-69.
22. Fernandes MT, Ferraro AA, de Azevedo RA, Fagundes Neto U. Metabolic differences between male and female adolescents with non-alcoholic fatty liver disease, as detected by ultrasound. Acta Paediatr. 2010;99:1218-23.
23. Hartmann P, Schnabl B. Risk factors for progression of and treatment options for NAFLD in children. Clin Liver Dis. 2018;11:11-5.
24. Nobili V, Socha P. Pediatric nonalcoholic fatty liver disease: current thinking. J Pediatr Gastroenterol Nutr. 2018;66:188-92.
25. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis. 2012;32:3-13.
26. Kwon Y, Jeong SJ. Relative skeletal muscle mass is an important factor in non-alcoholic fatty liver disease in non-obese children and adolescents. J Clin Med. 2020;9:3355.
27. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-835.
28. Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79:1212-9.
29. Wong VW, Chan WK, Chitturi S, et al. Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70-85.
30. Mendez-Sanchez N, Arrese M, Gadano A, et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2021;6:65-72.
31. Xing Y, Fan J, Wang HJ, Wang H. Comparison of MAFLD and NAFLD characteristics in children. Children. 2023;10:560.
32. Sessa A, Guarino S, Umano GR, Miraglia Del Giudice E, Marzuillo P. MASLD vs. NAFLD: a better definition for children with obesity at higher risk of kidney damage. J Hepatol. 2024;80:e87-9.
